What to Know About Tysabri and PML: Published Reports and Labeling Context

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one is taking Tysabri for multiple sclerosis, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wondered what early signs to watch for. Decades of pharmacovigilance and published case reports have established a clear link between natalizumab and PML, with risk factors now well-documented in the drug's labeling. This page reviews the published evidence and regulatory context to help you understand the condition and its monitoring.

Tysabri and PML: Mechanistic Link and Clinical Evidence

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, highlighting this risk and requiring that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML, with immediate withholding of dosing at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically involves brain imaging, cerebrospinal fluid analysis for JCV DNA, and sometimes brain biopsy. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage.

Risk Factors and Causation in Tysabri-Associated PML

Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore the importance of risk stratification and monitoring. The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which clearly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients and withhold dosing at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. However, despite these warnings, PML remains a serious adverse event, and causation considerations for affected patients involve evaluating the presence of these risk factors and the timeline between exposure and harm. The timeline between Tysabri exposure and documented PML can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability highlights the need for ongoing vigilance throughout treatment. For affected patients, establishing causation requires a thorough review of medical history, including prior immunosuppressant use, anti-JCV antibody status, and duration of Tysabri therapy. The presence of these risk factors strengthens the link between Tysabri and PML. In summary, Tysabri is associated with a significant risk of PML, as evidenced by clinical trial data and FDA-mandated warnings. The mechanistic pathway involves immune modulation that permits JCV reactivation. Risk factors are well-defined, and the timeline from exposure to harm can range from months to years. Adequate warnings exist, but the severity of PML necessitates careful patient selection and monitoring. For patients who develop PML, causation is supported by the presence of known risk factors and the temporal relationship with Tysabri use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Tysabri increases the risk of PML?

Tysabri (natalizumab) is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage characteristic of PML.

What are the primary risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.